Guava leaf diterpenes suppress Ehrlich ascites carcinoma cells in lab and mouse models
Two clerodane-type diterpenes isolated from Psidium guajava leaves showed measurable anticancer activity across cell-based, animal, and computational testing, with the strongest signal emerging from borapetoside F. The work focused on Ehrlich Ascites Carcinoma models, a classic experimental system often used to probe tumor growth suppression and apoptosis-related mechanisms. In practical terms, the study moves beyond crude plant extract claims and narrows the signal to two defined chemical entities: borapetoside F and borapetoside B. Both compounds were isolated from the ethyl acetate fraction of guava leaves and identified by nuclear magnetic resonance spectroscopy.
Borapetoside F produced the more pronounced response. In the in vitro MTT assay, it inhibited EAC cell growth by 82.4%, while borapetoside B inhibited growth by 79.8%. The in vivo arm, performed in EAC-bearing Swiss albino mice, also favored borapetoside F, which suppressed cell proliferation by 61.26% compared with 48.88% for borapetoside B. Those differences matter because tumor suppression in a living host is a higher bar than simple cytotoxicity in culture; the compound has to remain biologically active in the setting of absorption, distribution, and whole-organism metabolism.
The antitumor signal did not stop at viable cell counts.
Apoptosis signals aligned with the cytotoxic readouts
Microscopy and DNA fragmentation analysis pointed to apoptosis rather than random necrosis as the dominant mode of cell death. Optical and fluorescence imaging showed the expected morphological changes associated with apoptotic injury, and the DNA laddering pattern confirmed that the cells were not merely lysed; they were being driven through programmed death pathways. That distinction is clinically and biologically important because apoptosis often reflects pathway-specific interference with cancer cell survival machinery, rather than nonspecific toxicity.
Gene expression analysis reinforced that interpretation. Treatment increased expression of the pro-apoptotic markers p53, Bax, and Cytochrome C, while suppressing the anti-apoptotic genes Bcl-2 and NF-κB. In mechanistic terms, this pattern fits a shift toward mitochondrial apoptosis: Bax promotes membrane permeabilization, cytochrome c release activates downstream death signaling, and reduced Bcl-2 lowers the tumor cell’s ability to resist that cascade. NF-κB downregulation adds another layer, since this pathway often supports survival, inflammatory signaling, and resistance to cell death in malignant tissue.
One compact result captures the biological direction of travel: the compounds pushed the tumor cells toward death and away from survival.
Borapetoside F led the pair across the experimental cascade
The compound-level separation is worth keeping in view. Borapetoside F consistently outperformed borapetoside B in both the cell-based assay and the mouse experiment. For a natural product program, that kind of rank order is useful because it starts to define a lead structure rather than a generalized extract effect. It also suggests that relatively small differences in clerodane diterpene architecture may alter how the molecules engage apoptosis-related targets.
The isolation work itself was straightforward but important. Dried guava leaves were extracted with methanol, fractionated by modified Kupchan partitioning, and the ethyl acetate fraction was further purified by column chromatography and preparative thin-layer chromatography. The two final isolates were obtained in milligram quantities, with borapetoside F appearing as a yellow amorphous powder and borapetoside B as a white powder. Those yields are typical of discovery-stage natural products research, where the immediate goal is not production but structural identification and biological triage.
Docking data supported the apoptosis-linked mechanism
Molecular docking added a computational layer that aligned with the experimental findings. Both compounds showed favorable interactions with apoptosis-related target proteins, supporting the view that their cytotoxicity was not random. Docking cannot prove efficacy on its own, and it cannot replace pharmacokinetic or toxicity data, but it can strengthen a mechanistic story when the wet-lab results already point in the same direction. Here, the docking results were consistent with the observed changes in p53, Bax, cytochrome c, Bcl-2, and NF-κB expression.
In cancer drug development, that convergence matters. A molecule that suppresses proliferation, induces apoptotic morphology, fragments DNA, shifts gene expression in a pro-death direction, and fits apoptosis-related protein targets has a more credible translational profile than an extract that only reduces viability in one assay. Still, this remains a preclinical dataset. The study did not establish human dosing, therapeutic index, selectivity against normal tissue, or clinical activity in patients.
What the mouse experiment did, and did not, establish
The animal work used female Swiss albino mice and followed an in vivo schedule that included acclimatization, tumor inoculation, treatment, monitoring, and endpoint sacrifice within a 15-day framework. Humane endpoints were defined in advance, and no animals met those criteria before the end of the experiment. No deaths occurred during the study period. Those details support basic ethical conduct, but they do not answer the larger pharmacology questions that follow any promising anticancer signal: what exposure level is needed, what organ toxicities emerge first, and whether the compounds retain selectivity for malignant cells over normal tissue.
For now, the strongest claim is narrower and more concrete. Borapetoside F and borapetoside B, isolated from Psidium guajava leaves, showed significant anticancer activity against EAC cells and triggered apoptosis-linked molecular changes in both experimental and computational systems. Borapetoside F was the more active compound across the reported assays. The next step would have to move beyond proof-of-concept cytotoxicity and into dose optimization, safety profiling, and model systems that better predict human oncology use.